CO6801728A2 - Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis - Google Patents

Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis

Info

Publication number
CO6801728A2
CO6801728A2 CO13158421A CO13158421A CO6801728A2 CO 6801728 A2 CO6801728 A2 CO 6801728A2 CO 13158421 A CO13158421 A CO 13158421A CO 13158421 A CO13158421 A CO 13158421A CO 6801728 A2 CO6801728 A2 CO 6801728A2
Authority
CO
Colombia
Prior art keywords
lipomoses
adequate
formulation
treat
prevent tuberculosis
Prior art date
Application number
CO13158421A
Other languages
English (en)
Spanish (es)
Inventor
Pere Joan Cardona
Isabel Amat
Blanca Reyes
Ariadna Selga
Merce Amat
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11150072A external-priority patent/EP2471511A1/en
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of CO6801728A2 publication Critical patent/CO6801728A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO13158421A 2011-01-04 2013-07-04 Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis CO6801728A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11150072A EP2471511A1 (en) 2011-01-04 2011-01-04 Liposome formulation suitable for treating or preventing tuberculosis
EP11183487 2011-09-30

Publications (1)

Publication Number Publication Date
CO6801728A2 true CO6801728A2 (es) 2013-11-29

Family

ID=45509459

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13158421A CO6801728A2 (es) 2011-01-04 2013-07-04 Formulación de lipomosas adecuada para tratar o prevenir la tuberculosis

Country Status (18)

Country Link
US (1) US9877917B2 (enExample)
EP (1) EP2661253B1 (enExample)
JP (1) JP6096675B2 (enExample)
KR (1) KR101820026B1 (enExample)
CN (2) CN103796640A (enExample)
BR (1) BR112013017267B1 (enExample)
CA (1) CA2823747C (enExample)
CO (1) CO6801728A2 (enExample)
ES (1) ES2631556T3 (enExample)
HU (1) HUE032409T2 (enExample)
IL (1) IL227338B (enExample)
LT (1) LT2661253T (enExample)
MX (1) MX341918B (enExample)
PL (1) PL2661253T3 (enExample)
RU (1) RU2648842C2 (enExample)
SI (1) SI2661253T1 (enExample)
WO (1) WO2012093137A1 (enExample)
ZA (1) ZA201305697B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (zh) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 一种可变形脂质体的制备方法,及其制备的可变性脂质体
JP2016163851A (ja) * 2015-03-06 2016-09-08 国立大学法人福井大学 コンポジット型可溶化ナノリポソーム及びその製造方法
RU2631607C1 (ru) * 2016-11-22 2017-09-25 Владислав Николаевич Ласкавый Средство для профилактики лейкоза крупного рогатого скота и способ его применения
GB201707700D0 (en) * 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
CN109675059A (zh) * 2019-01-23 2019-04-26 青岛大学 一种类杆菌脂质体及其制备方法与应用
US11202823B2 (en) * 2019-04-05 2021-12-21 Northwestern University Multi-subunit vaccines to elicit both MHC- and CD1-restricted T cell responses
CN120456894A (zh) * 2021-10-14 2025-08-08 爱琴韦尔制药公司 用于治疗活动性结核病的脂质体制剂
CN115850520A (zh) * 2022-12-12 2023-03-28 中国农业大学 新型结核病亚单位疫苗al的制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900378A3 (en) * 1995-02-22 1999-11-29 Adcock Ingram Ltd A method for the isolation and purification of lipid cell-wall components
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US7393540B2 (en) 2001-07-04 2008-07-01 Health Protection Agency Mycobacterial antigens expressed during latency
BR0103887C1 (pt) * 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
EP1761662A4 (en) 2004-07-01 2010-02-03 Univ California PROTEOMICS WITH HIGH THROUGHPUT
PT2426141E (pt) * 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
CN101283085A (zh) * 2005-08-11 2008-10-08 哈佛大学的校长及成员们 用于干燥细胞形式的方法和组合物
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
US9393215B2 (en) * 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
US20090081284A1 (en) 2006-04-20 2009-03-26 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
HUE031951T2 (en) 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
ES2307402B1 (es) 2006-10-30 2009-09-30 Archivel Farma, S.L. Vacuna profilactica contra la tuberculosis.
BRPI0705630F8 (pt) * 2007-12-12 2022-01-18 Univ Estadual Campinas Unicamp Processo de produção de vacina gênica lipossomal, vacina gênica lipossomal e uso da mesma
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
ES2335177B1 (es) 2008-09-19 2011-02-28 Archivel Farma, S.L. Agente inmunoterapeutico apropiado para la profilaxis primaria de la tuberculosis.
EP2421557B1 (en) * 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
SG190937A1 (en) * 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition

Also Published As

Publication number Publication date
MX341918B (es) 2016-09-07
IL227338A0 (en) 2013-09-30
ZA201305697B (en) 2014-07-30
ES2631556T3 (es) 2017-09-01
RU2648842C2 (ru) 2018-03-28
MX2013007855A (es) 2013-10-25
PL2661253T3 (pl) 2017-08-31
US20150050327A1 (en) 2015-02-19
JP2014501768A (ja) 2014-01-23
HUE032409T2 (en) 2017-09-28
SI2661253T1 (sl) 2017-07-31
EP2661253A1 (en) 2013-11-13
RU2013136379A (ru) 2015-02-10
CA2823747A1 (en) 2012-07-12
IL227338B (en) 2019-01-31
CN107296793A (zh) 2017-10-27
US9877917B2 (en) 2018-01-30
BR112013017267A2 (pt) 2018-01-09
CA2823747C (en) 2019-07-23
WO2012093137A9 (en) 2012-12-27
EP2661253B1 (en) 2017-04-19
LT2661253T (lt) 2017-05-25
KR20140021538A (ko) 2014-02-20
JP6096675B2 (ja) 2017-03-15
BR112013017267B1 (pt) 2021-06-22
BR112013017267A8 (pt) 2018-11-06
CN103796640A (zh) 2014-05-14
KR101820026B1 (ko) 2018-01-18
WO2012093137A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
CO6791604A2 (es) Compuesto para liberación controlada de agentes de tratamiento de pozos
IL229474B (en) Cannabinoids for use in the treatment of neuropathic pain
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
CO6811868A2 (es) Combinaciones de principios activos
CO7061082A2 (es) Compuestos para tratar la artrofia muscular espinal
BR112015002704A2 (pt) superfícies sólidas e tratamentos antimicrobianos e processos para preparar os mesmos
CO6920291A2 (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante
CO7061086A2 (es) Combinaciones de compuestos activos
CO6930363A2 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
BR112013033444A2 (pt) formulações para terapia de ferida
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
EP2713762A4 (en) Stevia-COMPOSITION
PT2739268T (pt) Método e formulação para inalação
BR112013033720A2 (pt) método para tratar eczema
IL231061A0 (en) Antibacterial compounds and methods for use
BR112014013682A2 (pt) composição para cuidado pessoal
BR112014006291A2 (pt) composição e utilização da composição
BR112015002681A2 (pt) método para tratar um paciente e kit
HRP20182043T8 (hr) Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
EP2750709A4 (en) TREATMENT OF KACHEXIE
DK2522342T3 (da) Topisk formulering til behandling af hyperkeratonisk hud
BR112013008528A2 (pt) métodos para tratar psoríase
PL3400958T3 (pl) Kompozycje i metody leczenia celiakii